Login to Your Account

Pharma: Clinic Roundup

Tuesday, September 25, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said recruitment was completed for two randomized Phase III trials assessing the efficacy and safety of nintedanib (formerly BIBF 1120) 150 mg twice daily in idiopathic pulmonary fibrosis (IPF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription